A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

Shandong University

Status: Not yet enrolling

Conditions: Neuroendocrine Tumors

Treatments: Drug: Octreotide microspheres

Study type: Observational

Funder types: Other

Identifiers

NCT06300216

KYLL-202401-034-1

Details and patient eligibility

About

The aim of this multicenter, open-label, observational study is to evaluate the safety and efficacy of octreotide microspheres in the treatment of advanced neuroendocrine tumors in real clinical practice, especially to evaluate the treatment of octreotide microspheres in various subgroups of neuroendocrine tumor patients.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Sign an informed consent form and voluntarily participate in this study;
2. Patients with unresectable or metastatic neuroendocrine tumors confirmed by histopathology. Patients with recurrence and progression after surgery or local treatment can also be included in the study;
3. Age ≥ 18 years old;
4. Treatment with octreotide microspheres.

Exclusion criteria

1. Confirmed pregnant or lactating women;
2. Participating in any research with intervention measures outside of routine clinical practice;
3. Other situations unsuitable for inclusion in the study determined by the researcher.

Trial design

500 participants in 4 patient groups

Octreotide microspheres standard dose monotherapy

Treatment:

Drug: Octreotide microspheres

Octreotide microspheres standard dose combination therapy

Octreotide microspheres incremental or increased frequency therapy

Octreotide microspheres maintenance therapy after targeted or chemotherapy